Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743353 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
A Early Phase 1 study, sponsored by Siemens Molecular Imaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT00743353 is a Early Phase 1 study that has completed, run by Siemens Molecular Imaging. The registered enrollment target is 16 participants.
The verdict
NCT00743353, a Early Phase 1 study, has completed, sponsored by Siemens Molecular Imaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "\[F-18\] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic tumor. the system.
Interventions
- DRUG F-18 RGD-K5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743353
The ClinicalTrials.gov registry entry for NCT00743353 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Siemens Molecular Imaging, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which F-18 RGD-K5 is the first listed.
NCT00743353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743353 about?
NCT00743353 is a clinical study titled "Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5". The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "\[F-18\] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic ...
What is the current status of trial NCT00743353?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2008-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00743353?
The interventions under investigation include: F-18 RGD-K5 (DRUG).
Who is sponsoring clinical trial NCT00743353?
This trial is sponsored by Siemens Molecular Imaging, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.